VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE
· Real-Time Price · USD
0.40
-1.04 (-72.22%)
At close: Jul 30, 2025, 3:59 PM
VYNE Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -42.2M | -39.83M | -33.95M | -28.37M | -29.04M | -28.42M | -32.21M | -35.08M | -33.5M | -23.21M | -24.84M | -36.66M | -48.11M | -73.33M | -84.94M | -88.37M | -235.88M |
Depreciation & Amortization | -1.44M | -1.9M | -2.15M | -1.03M | -1.03M | -255K | -155K | 16K | 28K | 72K | 253K | 110K | 126K | 109K | 170K | 209K | 275K |
Stock-Based Compensation | 3.08M | 3.3M | 3.31M | 3.44M | 3.43M | 3.31M | 3.66M | 3.97M | 4.26M | 4.3M | 4.56M | 5.79M | 6.53M | 8.08M | 9.7M | 9.92M | 18.78M |
Other Working Capital | 11K | -23K | -957K | -441K | -669K | -703K | 2.87M | 2.29M | 11.96M | 2.3M | -2.07M | -4.82M | -10.71M | -576K | 13.23M | 17.59M | 11.06M |
Other Non-Cash Items | 1.78M | 3.88M | 3.37M | 906K | 2.32M | 997K | 2.33M | 2M | 1.05M | -12.72M | -11.7M | -10.22M | -10.35M | 2.47M | 1.26M | -58K | 138.87M |
Deferred Income Tax | n/a | n/a | 1.02M | 1.02M | 1.02M | 1.02M | n/a | n/a | n/a | n/a | 93K | 1.52M | 1.52M | 1.52M | 3.53M | 2.1M | 1.84M |
Change in Working Capital | 4.8M | 2.87M | 595K | -120K | -1.17M | 60K | 4.34M | 4.72M | 4.15M | 2.28M | -3.8M | -6.3M | -3.52M | 4.78M | -1.45M | -1.62M | -21.31M |
Operating Cash Flow | -37.45M | -33.97M | -30.11M | -26.75M | -27.84M | -25.34M | -24.08M | -26.05M | -24.7M | -29.2M | -35.34M | -45.76M | -53.79M | -56.37M | -71.72M | -77.82M | -97.42M |
Capital Expenditures | -117K | -117K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -113K | -113K | -184K |
Cash Acquisitions | n/a | n/a | -5M | -5M | -5M | n/a | 4.07M | 3.98M | 20.67M | 32.35M | 33.29M | 33.38M | 16.69M | n/a | -38.64M | -38.64M | -38.64M |
Purchase of Investments | -59.12M | -60.52M | -112.83M | -84.4M | -77.52M | -62.35M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 38.64M | 38.64M | 38.64M |
Sales Maturities Of Investments | 106M | 84M | 61.1M | 37.5M | 11.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.03M | 1.03M | 3.03M | 3.03M | 23.2M |
Other Investing Acitivies | -117K | -117K | 5M | 5M | 5M | 5M | -1.02M | -1.02M | -17.71M | -1.02M | n/a | n/a | 16.69M | n/a | 113K | 113K | 113K |
Investing Cash Flow | 46.77M | 23.36M | -51.73M | -46.9M | -65.92M | -57.35M | 4.07M | 3.98M | 3.98M | 15.67M | 16.6M | 16.69M | 17.71M | 1.03M | 3.03M | 3.03M | 23.13M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | -360K | -360K | -360K | -360K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -224K | -141K | -11K | -56K | -58K | -67K | 144K | 165K | 170K | 158K | -60K | -36.48M | -36.6M | -36.2M | -36.21M | 316K | 405K |
Financial Cash Flow | -224K | -141K | 82.65M | 82.61M | 82.61M | 82.39M | -61K | -40K | -96K | 1.65M | 1.41M | -32.13M | -32.19M | 39.78M | 47.8M | 81.44M | 135.17M |
Net Cash Flow | 9.09M | -10.75M | 817K | 8.95M | -11.16M | -301K | -20.07M | -22.11M | -20.82M | -11.88M | -17.33M | -61.2M | -68.27M | -15.56M | -20.9M | 6.64M | 60.91M |
Free Cash Flow | -37.57M | -34.09M | -30.11M | -26.75M | -27.84M | -25.34M | -24.08M | -26.05M | -24.7M | -29.2M | -35.34M | -45.76M | -53.79M | -56.37M | -71.84M | -77.93M | -97.61M |